Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study)
J Trelinska, I Dachowska, D Baranska… - Pediatric blood & …, 2017 - Wiley Online Library
J Trelinska, I Dachowska, D Baranska, K Stawiski, K Kotulska, W Fendler, S Jozwiak…
Pediatric blood & cancer, 2017•Wiley Online LibraryObjective One of the therapeutic options for patients with tuberous sclerosis (TCS) and
subependymal giant cell astrocytoma (SEGA) is everolimus treatment once daily, every day,
to attain trough concentrations of 5–15 ng/ml (standard treatment). The aim of this study was
to evaluate the efficacy and safety of a reduced dose of everolimus (three times a week with
a daily dose as in standard treatment—maintenance therapy) in a group of patients who
were previously treated with standard dose for at least 12 months. Materials and Methods …
subependymal giant cell astrocytoma (SEGA) is everolimus treatment once daily, every day,
to attain trough concentrations of 5–15 ng/ml (standard treatment). The aim of this study was
to evaluate the efficacy and safety of a reduced dose of everolimus (three times a week with
a daily dose as in standard treatment—maintenance therapy) in a group of patients who
were previously treated with standard dose for at least 12 months. Materials and Methods …
Objective
One of the therapeutic options for patients with tuberous sclerosis (TCS) and subependymal giant cell astrocytoma (SEGA) is everolimus treatment once daily, every day, to attain trough concentrations of 5–15 ng/ml (standard treatment). The aim of this study was to evaluate the efficacy and safety of a reduced dose of everolimus (three times a week with a daily dose as in standard treatment—maintenance therapy) in a group of patients who were previously treated with standard dose for at least 12 months.
Materials and Methods
Ten patients (six males, four females; median age 14.23 years) with TSC‐related SEGA who met inclusion criteria were included into a single‐arm, prospective trial. All the patients were followed over at least 12 months (median 12 and range 12–24 months). Tumor volumes from day 0, 90, 180, and 360 were evaluated by an experienced radiologist and an objective computer‐based method and compared. Adverse events (AEs) noted during maintenance therapy were compared to the AEs observed during standard everolimus therapy.
Results
The differences in SEGA volume between subsequent time points (day 0, 90, 120, and 360) were not statistically significant. No clinical symptoms of tumor regrowth were observed. AEs were significantly less severe and less frequent during maintenance compared with standard therapy.
Conclusions
Maintenance therapy with reduced‐dose everolimus is an effective therapeutic option for patients with TSC and SEGA after the completion of standard therapy and may moderate the rates of adverse effects.
Wiley Online Library